IBD patients have been found to have a higher risk of lymphoma.

Published Date: 26 Apr 2023

According to researchers from the Karolinska Institutet, patients with Crohn's disease and IBD have an elevated risk of developing lymphoma, and this risk has grown over the past few years.

Read Full News

Latest News

AGA Releases Updated Clinical Crohn’s Disease Guideline Reflecting New Therapies

AGA Releases Updated Clinical Crohn’s Disease Guideline Reflecting New Therapies

Reducing Diagnostic Delays and Improving Follow-Up Care for EoE, With Rosa Yu, MD

Reducing Diagnostic Delays and Improving Follow-Up Care for EoE, With Rosa Yu, MD

Small Intestine Dilation Links to Food-Protein-Induced Enterocolitis Syndrome Chelsie Derman

A recent study reveals that small intestinal dilation significantly contributes to abdominal symptoms in adults with Food-Protein-Induced Enterocolitis Syndrome (FPIES).

LUCENT-3: Mirikizumab (Omvoh) Shows Sustained Benefit in Ulcerative Colitis Through 4 Years Abigail Brooks, MA

LUCENT-3 open-label extension study data establish mirikizumab-mrkz (Omvoh) as the first and only IL-23p19 to show sustained long-term outcomes in UC through 4 years.

The HCPFive: Top News for Healthcare Providers from the Week of 10/05 HCPLive Editorial Staff

Stay updated with the latest healthcare breakthroughs, including FDA approvals and clinical trial readouts, in this week's essential news roundup.

HCPLive 5 Stories in Under 5: Week of 10/05 Victoria Johnson

An audio recap of the top 5 stories in healthcare news from the week of 10/5-10/11.

Todays Updates

How to Set a Biologic Strategy for Asthma, with Sara Assaf, MD Sara Assaf, MD

Assaf shares insights into how to navigate patient profiles and treatment options to optimize severe asthma care with biologics.

Natalizumab Biosimilar Officially Launched in the United States Marco Meglio

Natalizumab-sztn is an FDA-approved monotherapy for all indications of the reference product natalizumab, including relapsing forms of multiple sclerosis and Crohn disease.

GLP-1 Semaglutide Fails to Outperform Placebo in Phase 3 EVOKE Trial of Alzheimer Disease Isabella Ciccone, MPH

Results from the EVOKE and EVOKE+ phase 3 studies reported that oral semaglutide did not significantly reduce clinical progression in patients with early symptomatic Alzheimer disease.

FDA Approves New Intrathecal Administration Route for Spinal Muscular Atrophy Gene Therapy Marco Meglio

The FDA has approved Novartis’ intrathecal formulation of onasemnogene abeparvovec-brve, marketed as Itvisma, for patients ages 2 years and older living with spinal muscular atrophy.

Study Identifies Environmental Risk Factors Significantly Associated With Neuromyelitis Optica Spectrum Disorder Isabella Ciccone, MPH

Findings revealed that vitamin D deficiency was associated with an increased risk of NMOSD in East Asian populations, whereas the effect of smoking among Caucasians and other populations was inconsistent.

Advancing DM1 and DMD Care: Insights on DYNE-101 and DYNE-251 Development Marco Meglio

Doug Kerr, MD, PhD, chief medical officer at Dyne Therapeutics, discusses the clinical development of DYNE-101 for myotonic dystrophy type 1 and DYNE-251 for Duchenne muscular dystrophy.

Discussing New Topical Drugs for Atopic Dermatitis in Younger Patients, With Peter Lio, MD Peter Lio, MD

This Fall Clinical Dermatology Conference interview features Peter Lio, MD, discussing takeaways from several of his sessions at the meeting.

Todays Updates

How to Set a Biologic Strategy for Asthma, with Sara Assaf, MD Sara Assaf, MD

Assaf shares insights into how to navigate patient profiles and treatment options to optimize severe asthma care with biologics.

Natalizumab Biosimilar Officially Launched in the United States Marco Meglio

Natalizumab-sztn is an FDA-approved monotherapy for all indications of the reference product natalizumab, including relapsing forms of multiple sclerosis and Crohn disease.

GLP-1 Semaglutide Fails to Outperform Placebo in Phase 3 EVOKE Trial of Alzheimer Disease Isabella Ciccone, MPH

Results from the EVOKE and EVOKE+ phase 3 studies reported that oral semaglutide did not significantly reduce clinical progression in patients with early symptomatic Alzheimer disease.

FDA Approves New Intrathecal Administration Route for Spinal Muscular Atrophy Gene Therapy Marco Meglio

The FDA has approved Novartis’ intrathecal formulation of onasemnogene abeparvovec-brve, marketed as Itvisma, for patients ages 2 years and older living with spinal muscular atrophy.

Study Identifies Environmental Risk Factors Significantly Associated With Neuromyelitis Optica Spectrum Disorder Isabella Ciccone, MPH

Findings revealed that vitamin D deficiency was associated with an increased risk of NMOSD in East Asian populations, whereas the effect of smoking among Caucasians and other populations was inconsistent.

Advancing DM1 and DMD Care: Insights on DYNE-101 and DYNE-251 Development Marco Meglio

Doug Kerr, MD, PhD, chief medical officer at Dyne Therapeutics, discusses the clinical development of DYNE-101 for myotonic dystrophy type 1 and DYNE-251 for Duchenne muscular dystrophy.

Discussing New Topical Drugs for Atopic Dermatitis in Younger Patients, With Peter Lio, MD Peter Lio, MD

This Fall Clinical Dermatology Conference interview features Peter Lio, MD, discussing takeaways from several of his sessions at the meeting.

Latest News

AGA Releases Updated Clinical Crohn’s Disease Guideline Reflecting New Therapies

Reducing Diagnostic Delays and Improving Follow-Up Care for EoE, With Rosa Yu, MD

A recent study reveals that small intestinal dilation significantly contributes to abdominal symptoms in adults with Food-Protein-Induced Enterocolitis Syndrome (FPIES).

LUCENT-3 open-label extension study data establish mirikizumab-mrkz (Omvoh) as the first and only IL-23p19 to show sustained long-term outcomes in UC through 4 years.

Stay updated with the latest healthcare breakthroughs, including FDA approvals and clinical trial readouts, in this week's essential news roundup.

An audio recap of the top 5 stories in healthcare news from the week of 10/5-10/11.

News All Time

GLP-1 RAs Reduce Anemia Risk in Patients with Celiac Disease Abigail Brooks, MA

GLP-1 RA use was linked to a significant survival benefit and reduced risk of iron deficiency anemia in patients with celiac disease.

1 in 10 People Without Celiac Disease Report Gluten or Wheat Sensitivity Chelsie Derman

Study finds non-celiac gluten or wheat sensitivity is more common in women and linked to IBS, anxiety, and depression.

Closing the Diagnostic Gap in Eosinophilic Esophagitis, With Walker Redd, MD Walker Redd, MD

Redd reviews real-world data highlighting low rates of biopsies performed among patients with esophageal food impaction-related emergency department visits.

Don't let food poisoning crash your Thanksgiving dinner

Thanksgiving is a time for family, friends and feasting. However, amid the joy of gathering and indulging in delicious food, it is essential to keep food safety in mind. Foodborne illnesses can quickly put a damper on your ...

How the gut builds long-lasting immunity after viral infections

A new study led by University of Toronto researchers has shown that immune cells in the gut follow an atypical pathway to produce antibodies that provide long-term protection against viruses.

New drug offers hope to bladder cancer patients

Imagine a targeted approach to bladder cancer that spares healthy cells while delivering chemotherapy directly to cancerous ones, offering hope for patients with advanced stages of the disease.

Medications change our gut microbiome in predictable ways, research reveals

Our gut microbiome is made up of trillions of bacteria and other microbes living in our intestines. These help our bodies break down food, assist our immune system, send chemical signals to our brain, and potentially serve ...

Researchers find simple way to make kale healthier by pairing it with oil-based dressings

Think that kale salad you're eating is a superfood? Without the right ingredient it might not be living up to its hype. But don't worry.

How weakness in cell structure affects the host–microbiome relationship

Cells have an internal skeleton that maintains their structure and also drives their movement. Known as the cytoskeleton, this scaffold is composed of a network of dynamic filaments made of a protein called actin.

Scientists map the cells that drive Crohn's disease fistulas

Scientists at the University of Oxford, have identified how rare populations of abnormal cells drive the formation and persistence of fistulas—painful, tunnel-like tracts that develop in around 30% of people with Crohn's ...

AI analyzes multiple physicians' notes to improve diagnosis of complex liver condition

Taking a page from market research tactics, UC San Francisco experts are studying whether artificial intelligence (AI) can improve diagnosis of a complex liver condition by using the clinical notes of multiple providers.

Ultra-processed foods tied to higher rates of early-onset colorectal cancer precursors in adults

Colorectal cancer used to be associated with old age, but diagnoses have become increasingly common in adults aged 50 or younger particularly in high-income countries like the United States. The reason for this trend is unclear, ...

Pill-induced esophagitis: Why your medication could be damaging your throat and what to do about it

Every year, people around the world take an astonishing 3.8 trillion doses of medicine. Most of these medicines are swallowed rather than injected or inhaled, because the oral route is the easiest, safest and most familiar ...

Can't sleep? Your microbiome may play a role

Sleep is a hot commodity—we want it, we need it, but most of us aren't getting enough of it.

Plants adapting to climate change may help IBD treatment

James Cook University (JCU) researchers have discovered that the same chemical compounds produced by mountain-top plants to help them survive climate change in North Queensland may also hold promise for treating inflammatory ...

High-risk individuals who have mild dilation of pancreatic duct have increased risk for pancreatic cancer, study finds

Pancreatic ductal adenocarcinoma is projected to become the second-leading cause of cancer death in the United States by 2030, according to the National Institutes of Health (NIH). The International Cancer of the Pancreas ...

Recommended News For You

Lung nodules seen in a high percentage of non-smokers

Emicizumab in Infants With Hemophilia A: Safe and Effective Use.

Child Death Rates Are Rising in the U. s. ; Water Beads Warning; Cancer Studies Retracted.

In patients with prostate cancer, second-generation antiandrogens may worsen fatigue, falls, and cognitive decline.

Two-part prodrug system activates immune attack only in tumor's unique environment

Making informed decisions and managing regret after prostate cancer treatment

For patients with clear cell renal cell carcinoma, a new PET agent allows for same-day imaging.

Recommended Articles For You

Recent Advances in Paroxysmal Nocturnal Hemoglobinuria Research: Promising Therapies on the Horizon  

Late Effects of Immunotherapy in Chronic Melanoma Survivorship with Repurposed Drugs 

AI in the War on Cancer: How Digital Tools are Revolutionizing Oncology 

Uncovering the Subtle Signs of Prostate Cancer: Early Detection is Key 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Q&A: Why adolescents and young adults with cancer are falling behind

2.

Novel probes to label macrophages associated with cancer progression using a selective dye

3.

A Possible Novel CAR-T Treatment for High-Risk R/R Follicular Lymphoma May Be Liso-Cel.

4.

Prostate cancer, rectal exams, Casgevy approved for thalassemia, and two million cancer cases.

5.

Exercise could ease symptoms for people with chronic lymphocytic leukemia, support and guidance are lacking: Study

1.

Chemotherapy Advances: Albumin I.V., Trastuzumab, Liposomal Doxorubicin & More

2.

Understanding Melanoma: From Diagnosis to Healing and Excision in Denver

3.

A Clinical Review of Novel Therapeutics for Rare Cancers in the Genomics Era

4.

Recent Advances in Paroxysmal Nocturnal Hemoglobinuria Research: Promising Therapies on the Horizon 

5.

Exploring the Benefits of Teclistamab for Treating Advanced Cancer

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion

2.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VIII

3.

An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion IV

4.

Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma

5.

Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part V

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot